Impact of adjuvant lorazepam with granisetron on chemotherapy-induced nausea and vomiting in pediatric patients with acute lymphoblastic leukemia

[1]  D. Tsuji,et al.  Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy , 2017, Supportive Care in Cancer.

[2]  A. McCarthy,et al.  The Effect of a Standardized Ginger Extract on Chemotherapy-Induced Nausea-Related Quality of Life in Patients Undergoing Moderately or Highly Emetogenic Chemotherapy: A Double Blind, Randomized, Placebo Controlled Trial , 2017, Nutrients.

[3]  M. Kris,et al.  Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  E. Loeffen,et al.  The importance of evidence-based supportive care practice guidelines in childhood cancer—a plea for their development and implementation , 2016, Supportive Care in Cancer.

[5]  E. Bruera,et al.  2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  C. Portwine,et al.  Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy‐Induced Nausea and Vomiting in Children With Cancer , 2016, Pediatric blood & cancer.

[7]  K. Eguchi,et al.  Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary , 2015, International Journal of Clinical Oncology.

[8]  Alexandra Shillingburg,et al.  Aprepitant and fosaprepitant use in children and adolescents at an academic medical center. , 2014, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.

[9]  C. Portwine,et al.  Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients , 2013, Pediatric blood & cancer.

[10]  K. Kubota,et al.  Risk factors of chemotherapy‐induced nausea and vomiting: Index for personalized antiemetic prophylaxis , 2013, Cancer science.

[11]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[12]  Kamakshi V. Rao,et al.  Chemotherapy-induced nausea and vomiting: optimizing prevention and management. , 2012, American health & drug benefits.

[13]  M. Kris,et al.  Antiemetics: American Society of Clinical Oncology clinical practice guideline update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Kris,et al.  Antiemetics: American Society of Clinical Oncology clinical practice guideline update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  C. Portwine,et al.  Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients , 2011, Pediatric blood & cancer.

[16]  M. Tonato,et al.  Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only) , 2011, Supportive Care in Cancer.

[17]  Chihiro Hata,et al.  Clonazepam use for prevention of acute and delayed vomiting induced by Cisplatin-based chemotherapy for lung cancer. , 2010, Biological & pharmaceutical bulletin.

[18]  P. Nathan,et al.  Optimizing Emetic Control in Children Receiving Antineoplastic Therapy , 2010, Pediatric Drugs.

[19]  F. Roila,et al.  Acute emesis: moderately emetogenic chemotherapy , 2010, Supportive Care in Cancer.

[20]  C. Portwine,et al.  Symptom assessment in children receiving cancer therapy: the parents’ perspective , 2010, Supportive Care in Cancer.

[21]  R. Riccardi,et al.  Pharmacological Management of Chemotherapy-Induced Nausea and Vomiting in Children with Cancer , 2009, Journal of chemotherapy.

[22]  E. López-Aguilar,et al.  Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children. , 2008, Archives of medical research.

[23]  P. Hesketh.  Chemotherapy-induced nausea and vomiting. , 2008, The New England journal of medicine.

[24]  A. Taddio,et al.  Development and Validation of the Pediatric Nausea Assessment Tool for Use in Children Receiving Antineoplastic Agents , 2006, Pharmacotherapy.

[25]  M. Kris,et al.  American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Holdsworth,et al.  Acute and delayed nausea and emesis control in pediatric oncology patients , 2006, Cancer.

[27]  J. Koeller,et al.  Acute emesis: moderately emetogenic chemotherapy , 2005, Supportive Care in Cancer.

[28]  M. Tonato,et al.  Delayed emesis: moderately emetogenic chemotherapy , 2005, Supportive Care in Cancer.

[29]  J. Osterhaus,et al.  Quality of life consequences of chemotherapy-induced emesis , 1992, Quality of Life Research.

[30]  P. Nathan,et al.  Options for the Prevention and Management of Acute Chemotherapy-Induced Nausea and Vomiting in Children , 2003, Paediatric drugs.

[31]  J. Harousseau,et al.  Amélioration du contrôle des nausées et vomissements lors d’une chimiothérapie modérément émétisante, par l’association ondansétron méthylprednisolone etlorazépam, chez des patients en échec d’une association antiémétique antérieure , 2000 .

[32]  R. Zittoun,et al.  [Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination]. , 2000, Bulletin du cancer.

[33]  M. Qazilbash,et al.  Clinical Efficacy of Lorazepam in Prophylaxis of Anticipatory, Acute, and Delayed Nausea and Vomiting Induced by High Doses of Cisplatin: A Prospective Randomized Trial , 1995, American journal of clinical oncology.

[34]  M. Ahn,et al.  A Randomized Double‐Blind Trial of Ondansetron Alone Versus in Combination with Dexamethasone Versus in Combination with Dexamethasone and Lorazepam in the Prevention of Emesis Due to Cisplatin‐Based Chemotherapy , 1994, American journal of clinical oncology.

[35]  C. Pui,et al.  Chlorpromazine with and without lorazepam as antiemetic therapy in children receiving uniform chemotherapy. , 1993, The Journal of pediatrics.

[36]  M. Piccart,et al.  Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  G. Martinelli,et al.  The antiemetic activity of high-dose metoclopramide and high-dose alizapride in combination with lorazepam in patients receiving cancer chemotherapy. A prospective, randomized, double-blind study. , 1991, Oncology.

[38]  L. Crumpler,et al.  Lorazepam in cancer patients treated with cisplatin: a drug having antiemetic, amnesic, and anxiolytic effects. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  S. Bowcock,et al.  Antiemetic prophylaxis with high dose metoclopramide or lorazepam in vomiting induced by chemotherapy. , 1984, British medical journal.

[40]  T. Mughal.  Improved Tolerance of Cytotoxic Chemotherapy with Lorazepam , 1983 .

[41]  T. Mughal.  Improved tolerance of cytotoxic chemotherapy with lorazepam. A pilot study. , 1983, Oncology.